RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Coherus BioSciences Stock

Coherus BioSciences Liabilities 2024

Coherus BioSciences Liabilities

823.03 M USD

Ticker

CHRS

ISIN

US19249H1032

WKN

A12ETZ

In 2024, Coherus BioSciences's total liabilities amounted to 823.03 M USD, a 33.11% difference from the 618.3 M USD total liabilities in the previous year.

Coherus BioSciences Aktienanalyse

What does Coherus BioSciences do?

Coherus BioSciences Inc is a pharmaceutical company specializing in the development and marketing of biosimilars. The company was founded in California in 2010 and has since focused on the development of biopharmaceuticals. Coherus BioSciences Inc's history began with the acquisition of the biomanufacturing facility from PDL BioPharma, a company specialized in the development and marketing of therapeutics and biologics. Coherus BioSciences Inc used the facility to build a portfolio of biosimilars. Coherus BioSciences Inc's business model is based on the sale of biosimilars, which offer a cost-effective alternative to expensive biologics. Biosimilars are biopharmaceuticals that are manufactured similarly to already approved biologics, but can be offered at a lower price. Coherus BioSciences Inc specializes in the development and marketing of biosimilars in the fields of oncology, immunology, and neurology. The products that the company currently brings to market or is developing include biosimilar versions of Enbrel, Neulasta, and Humira. Enbrel is a biologic used to treat rheumatoid arthritis, psoriasis, and other inflammatory conditions. Neulasta is a medication used to support white blood cells after chemotherapy, while Humira is a medication used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. Coherus BioSciences Inc has also launched a collaboration with Novartis to develop a biosimilar version of Lucentis. Lucentis is a biologic used to treat age-related macular degeneration. Overall, Coherus BioSciences Inc has built a portfolio of ten biosimilars and is working to bring more products to market. The company has also conducted several preclinical and clinical studies to demonstrate the efficacy and safety of its biosimilars. Coherus BioSciences Inc is headquartered in Redwood City, California. The company currently employs over 140 employees and has offices in the USA, Europe, and Asia. Overall, Coherus BioSciences Inc has played a groundbreaking role in the development of cost-effective biosimilars. The company specializes in the marketing of biosimilars and offers a range of products in the fields of oncology, immunology, and neurology. Coherus BioSciences Inc has also launched a collaboration with another company to develop a biosimilar version of Lucentis. The company has built a portfolio of ten biosimilars and is constantly expanding its offerings. Coherus BioSciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Coherus BioSciences's Liabilities

Coherus BioSciences's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Coherus BioSciences's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Coherus BioSciences's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Coherus BioSciences's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Coherus BioSciences’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Coherus BioSciences stock

What is the level of liabilities of Coherus BioSciences this year?

Coherus BioSciences has a debt balance of 823.03 M USD this year.

What were the liabilities of Coherus BioSciences compared to the previous year?

The liabilities of Coherus BioSciences have increased by 33.11% increased compared to the previous year.

What are the consequences of high debt for investors of Coherus BioSciences?

High liabilities can pose a risk for investors of Coherus BioSciences, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Coherus BioSciences?

Low liabilities mean that Coherus BioSciences has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Coherus BioSciences affect the company?

An increase in liabilities of Coherus BioSciences can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Coherus BioSciences affect the company?

A decrease in the liabilities of Coherus BioSciences can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Coherus BioSciences?

Some factors that can influence the liabilities of Coherus BioSciences include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Coherus BioSciences so important for investors?

The liabilities of Coherus BioSciences are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Coherus BioSciences take to modify the liabilities?

To change its liabilities, Coherus BioSciences can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Coherus BioSciences pay?

Over the past 12 months, Coherus BioSciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Coherus BioSciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Coherus BioSciences?

The current dividend yield of Coherus BioSciences is .

When does Coherus BioSciences pay dividends?

Coherus BioSciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Coherus BioSciences?

Coherus BioSciences paid dividends every year for the past 0 years.

What is the dividend of Coherus BioSciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Coherus BioSciences located?

Coherus BioSciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Coherus BioSciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Coherus BioSciences from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did Coherus BioSciences pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of Coherus BioSciences in the year 2023?

In the year 2023, Coherus BioSciences distributed 0 USD as dividends.

In which currency does Coherus BioSciences pay out the dividend?

The dividends of Coherus BioSciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Coherus BioSciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Coherus BioSciences

Our stock analysis for Coherus BioSciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Coherus BioSciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.